Drug Profile
Research programme: MRSA monoclonal antibody prophylactics and therapeutics - Codevax
Alternative Names: MRSA MAb; MRSA monoclonal antibodyLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Codevax
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in USA
- 16 Jul 2010 Preclinical trials in Methicillin-resistant Staphylococcus aureus infections in USA (unspecified route)